Sarah Gitto, PhD
Itmat Expertise
Immunotherapy, Ovarian Cancer, Tumor Immunology, Tumor Microenvironment, PDX modeling
Education
B.S. (Molecular Biology and Microbiology), University of Central Florida, 2011
B.S. (Health Sciences, Pre-Clinical Track ), University of Central Florida, 2011
M.S. (Biomedical Sciences), University of Central Florida, 2014
Ph.D. (Biomedical Sciences), University of Central Florida, 2017
M.S. (Translational Science), University of Pennsylvania, 2022
Specialty Certification
Postgraduate Training
Post-doctoral Fellow, University of Pennsylvania, 2018-2022
Awards and Honors
Undergraduate Research Initiative Award, University of Central Florida, 2011
Graduate Research Excellence Fellowship, University of Central Florida, 2014-2016
Graduate Student Mentoring Scholarship, UCF Learning Environment and Academic Research Network (L.E.A.R.N.), 2015-2016
Young Alumni Chapter Scholarship, UCF Alumni Association, 2015-2016
Graduate Student Mentoring Scholarship, UCF Learning Environment and Academic Research Network (L.E.A.R.N.), 2016-2017
Order of Pegasus, University of Central Florida, 2016
Award for Excellence by a Graduate Teaching Assistant, University of Central Florida, 2016-2017
Award for Excellence by a Graduate Teaching Assistant, UCF College of Medicine, 2016
Fellows Graduate Student Scholarship, UCF Alumni Associaton, 2016-2017
Presentation Travel Fellowship, University of Central Florida, 2016
Director’s Travel Award, UCF Burnett School of Biomedical Sciences, 2016
Outstanding Student Leader, UCF L.E.A.D. Scholars Academy, 2016
College of Medicine Founder's Scholarship, University of Central Florida, 2016
Rosa Parks Community Service Scholarship, University of CEntral Florida, 2017
Graduate Fellows Leadership Scholarship, UCF Alumni Association, 2017
30 Under 30, UCF Alumni Association, 2018
Institute for Translational Medicine and Therapeutics Scholarship, University of Pennsylvania, 2020-2022
Society of ImmunoTherapy of Cancer (SITC), Accelerator Program, 2021-2023
Post-Doctoral Travel Award, Translational Research Cancer Consortium, 2022
SITC Woman in Immunotherapy Newtwork Leadership Institute, 2023
Arthur and Sandra Irving Cancer Immunology Symposium, 2023
Early Career Enhancement Award, Hopkins-UPenn Ovarian Cancer SPORE, 2023-2024
NIC-NCI Loan Forgiveness Program (LRP) Award, 2024-2026
Memberships and Professional Organizations
Society for Free Radical Biology and Medicine, 2011 - 2017
Biomedical Sciences Graduate Student Association, University of Central Florida, 2012 - 2017
Delta Epsilon Iota Academic Honor Society, 2012 - 2017
American Association for the Advancement of Science, 2015 - 2017
Graduate Student Association, University of Central Florida, 2015 - 2017
American Association for Cancer Research, 2016 - Present
American Society of Clinical Oncology, 2016 - Present
Society for ImmunoTherapy of Cancer, 2019 - Present
Web Links
Selected Publications
Time-driven dosimetry tool for in-vitro RPT experiments.
Onecha VV, Bosque J, Suarez-Garcia D, Gitto SB, Ihewulezi C, Lee H, Pryma DA, Bertolet A, AAPM 66th Annual Meeting and Exhibition, 2024
Space-and time-heterogeneous dosimetry for in vivo targeted alpha therapy
Onecha VV, Suarez-Garcia D, Gitto SB, Lee H, Ihewulezi CN, Pryma D, Bertolet A, Journal of Nuclear Medicine, 2024
PET imaging of PARP expression as a biomarker of response to chemotherapy in breast cancer: A nonrandomized clinical trial.
Gitto SB, Young A, Bleiweiss I, Clark A, McDonald E., Cancer Research 84(): PS05-02, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Xu H*, Gitto SB*, Ho GY*, Medvedev S, Shield-Artin KL, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT, Australian Ovarian Cancer Study, Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F., iScience, 2024
A B7H4 targeting antibody-drug conjugate shows anti-tumor activities in PARPi and platinum resistant cancers with B7-H4 expression.
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Lewis A, Mamidi S, Medvedev S, Anderton J, Tang EJ, Ferman B, Coates S, Wilkinson RW, Brown E, Powell DJ Jr., Simpkins F., Clinical Cancer Research, 2024
Adoptive T cell therapy for ovarian cancer
Gitto SB, Ihewulezi CN, Powell DJ Jr, Gynecology Oncology, 2024
PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival
Oyer JL, Croom-Perez TJ, Hasan MF, Rivera-Huertas JA, Gitto SB, Mucha JM, Altomare DA, Igarashi RY, Copik AJ, Frontiers in Immunology, 2024
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Tubridy EA, Eiva MA, Lui F, Omran DK, Gysler S, Brown EG, Roy AG, Zang Y, Oh J, Cao Q, Gitto SB, Powell DJ Jr., Gynecology Oncology, 2024
Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer.
5. Kinose Y, Xu H, Kumar S, Kim H, Medvedev S, Wang X, George E, Shan X, Gitto SB, D’Andrea K, Wubbenhorst B, Whicker M, Hallberg D, Schwartz L, Nathenson KL, Mills G, Velculescu VE, Wang TL, Brown E, Drapkin R, Simpkins F, Molecular Cancer Therapeutics, 2023
Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancers.
Kinase Y*, Xu H*, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D’Andrea K, Wubbenhorst B, Hallberg D, O’Connor M, Schwartz L, Hwang W, Nathanson KL, Mills G, Velculescu VE, Wang T, Brown E, Drapkin R, Simpkins F, Research Square (pre-print)., 2023
